References
- Del Rosso J Q, Zellis S, Gupta A K. Itraconazole in the treatment of superficial cutaneous and mucosal Candida infection. J Am Osteopath Assoc 1998; 9: 497–502
- Grant S M, Clissold S P. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310–44
- Lachapelle J M, De Doncker P, Tennstedt D, et al. Itraconazole compared with griseofulvin in the treatment of tinea corporis/cruris and tinea pedis/manuum: an interpretation of the clinical results of all completed double-blind studies with respect to the pharmacokinetic profile. Dermatology 1992; 184: 45–50
- Roseeuw D, De Doncker P. New approaches to the treatment of onychomycosis. J Am Acad Dermatol 1993; 29: S45–S50
- Davies R R, Everall J D, Hamilton E. Mycological and clinical evaluation of griseofulvin for chronic onychomycosis. BMJ 1967; 3: 464–8
- Cauwenbergh G. New and prospective developments in antifungal drugs. Acta Derm Venereol (Stockh) 1986; 121: 147–53
- Kay R J. Superficial and deep mycosis: the extent of the problem. Ketoconazole in the management of fungal disease, H B Levine. Adis Press, Hong Kong 1982
- Gupta A, De Doncker P, Heremans A, et al. Itraconazole in tinea pedis: a dose of 400 mg/day given for 1 week is more effective than 100 or 200 mg/day given for 2–4 weeks. J Eur Acad Dermatol Venereol 1995; 5(Suppl 1)S173
- Parent D, Decorix J, Heenen M. Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and/or tinea cruris. Dermatology 1994; 189(4)378–81
- Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol 1997; 52: 235–7
- Del Rosso J Q, Gupta A K. Oral antifungal agents: recognition and management of adverse reactions. Today Ther Trends 1997; 15(2)75–84
- De Doncker Gupta A K, Marynissen G, et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 1997; 37: 969–74